BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34090412)

  • 21. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
    Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
    Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.
    Martelli MP; Sozzi G; Hernandez L; Pettirossi V; Navarro A; Conte D; Gasparini P; Perrone F; Modena P; Pastorino U; Carbone A; Fabbri A; Sidoni A; Nakamura S; Gambacorta M; Fernández PL; Ramirez J; Chan JK; Grigioni WF; Campo E; Pileri SA; Falini B
    Am J Pathol; 2009 Feb; 174(2):661-70. PubMed ID: 19147828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.
    Wang R; Deng X; Yoshioka Y; Vougiouklakis T; Park JH; Suzuki T; Dohmae N; Ueda K; Hamamoto R; Nakamura Y
    Cancer Sci; 2017 Jun; 108(6):1203-1209. PubMed ID: 28370702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
    Shibahara D; Tanaka K; Iwama E; Kubo N; Ota K; Azuma K; Harada T; Fujita J; Nakanishi Y; Okamoto I
    J Thorac Oncol; 2018 Jul; 13(7):926-937. PubMed ID: 29596910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
    Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
    Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
    Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
    Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
    Wong DW; Leung EL; So KK; Tam IY; Sihoe AD; Cheng LC; Ho KK; Au JS; Chung LP; Pik Wong M;
    Cancer; 2009 Apr; 115(8):1723-33. PubMed ID: 19170230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer.
    Tan S; Sun D; Pu W; Gou Q; Guo C; Gong Y; Li J; Wei YQ; Liu L; Zhao Y; Peng Y
    Mol Cancer; 2018 Sep; 17(1):138. PubMed ID: 30236141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
    Bayliss R; Choi J; Fennell DA; Fry AM; Richards MW
    Cell Mol Life Sci; 2016 Mar; 73(6):1209-24. PubMed ID: 26755435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells.
    Yeh CT; Huang WC; Rao YK; Ye M; Lee WH; Wang LS; Tzeng DT; Wu CH; Shieh YS; Huang CY; Chen YJ; Hsiao M; Wu AT; Yang Z; Tzeng YM
    Carcinogenesis; 2013 Dec; 34(12):2918-28. PubMed ID: 23880305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells.
    Gao Y; Liu T; Liu J; Yang Y; Sun K; Li Z; Zhai X; Zuo D
    Chem Biol Interact; 2023 Jul; 379():110516. PubMed ID: 37116853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.
    Wu YC; Chang IC; Wang CL; Chen TD; Chen YT; Liu HP; Chu Y; Chiu YT; Wu TH; Chou LH; Chen YR; Huang SF
    PLoS One; 2013; 8(8):e70839. PubMed ID: 23951022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.
    Cheon SY; Kwon S
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mesenchymal morphology of cells expressing the EML4-ALK V3 oncogene is dependent on phosphorylation of Eg5 by NEK7.
    Pashley SL; Papageorgiou S; O'Regan L; Barone G; Robinson SW; Lucken K; Straatman KR; Roig J; Fry AM
    J Biol Chem; 2024 May; 300(5):107144. PubMed ID: 38458397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK.
    Penzel R; Schirmacher P; Warth A
    J Thorac Oncol; 2012 Jul; 7(7):1198-9. PubMed ID: 22706607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
    Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F
    Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitive detection of EML4-ALK fusion oncoprotein of lung cancer by in situ proximity ligation assay.
    Rho JK; Lee H; Park CS; Choi CM; Lee JC
    Clin Chem Lab Med; 2013 Sep; 51(9):1843-8. PubMed ID: 23612660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues.
    Sozzi G; Martelli MP; Conte D; Modena P; Pettirossi V; Pileri SA; Falini B
    Haematologica; 2009 Sep; 94(9):1307-11. PubMed ID: 19734424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
    Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K
    Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.